The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 25, 2018

Filed:

Mar. 31, 2015
Applicants:

Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, CN;

Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, CN;

Inventors:

Xin Li, Shanghai, CN;

Wei He, Shanghai, CN;

Xianbo Liu, Shanghai, CN;

Bin Wang, Shanghai, CN;

Qiyue Hu, Shanghai, CN;

Fangfang Jin, Shanghai, CN;

Qing Dong, Shanghai, CN;

Piaoyang Sun, Jiangsu, CN;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 307/78 (2006.01); C07D 307/87 (2006.01); C07D 471/04 (2006.01); C07C 233/47 (2006.01); C07C 233/63 (2006.01); C07D 209/10 (2006.01); C07D 209/44 (2006.01); C07D 231/56 (2006.01); C07D 235/18 (2006.01); C07D 263/57 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); C07C 233/47 (2013.01); C07C 233/63 (2013.01); C07D 209/10 (2013.01); C07D 209/44 (2013.01); C07D 231/56 (2013.01); C07D 235/18 (2013.01); C07D 263/57 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07C 2601/02 (2017.05);
Abstract

Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof are provided. Specifically, amide derivatives represented by general formula (I) are provided. The amide derivatives represented by general formula (I) can be used as a therapeutic agent, particularly as an inhibitor for microsomal prostaglandin E synthase-1 (mPGES-1), and also to treat and/or prevent diseases or illnesses such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.


Find Patent Forward Citations

Loading…